CSF3 and non-Hodgkin lymphoma: The combination of plerixafor and G-CSF has been approved by the US Food and Drug Administration (FDA) for mobilization of autologous transplantation in patients with multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) since 2008.